11 research outputs found

    Angiogenic factors in TAO.

    No full text
    <p>MMP-8 = matrix metalloproteinase-8, VEGF = vascular endothelial growth factor; NS = nonsmokers, S = smokers, TAO = Thromboangiitis obliterans.</p

    Serum of TAO patients inhibits HUVEC migration.

    No full text
    <p>Scratch wound closure assay; a single scrape was made across a confluent HUVEC monolayer (Baseline). The extent of regrowth to close the scratch wound was measured after 6 hours (6 h) incubation in medium containing 10% of serum of TAO patients or controls. Data are presented as medians, with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n = 12 in each group). ***P<0.001; NS = nonsmokers, S = smokers, TAO = Thromboangiitis obliterans.</p

    Serum of TAO patients inhibits HUVEC proliferation by changes in cell cycle progression.

    No full text
    <p>A) HUVECs were incubated for 24 hours with 10% serum of TAO patients and controls and proliferation was determined as doubling time in hours. Data are presented as medians, with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n = 12 in each group). *P<0.05, **P<0.01, ***P<0.001. B) For cell cycle analysis HUVECs were cultured for 24 hours with 10% serum of TAO patients and controls, and DNA content was measured by flow cytometry. NS = nonsmokers, S = smokers, TAO = Thromboangiitis obliterans.</p

    Proliferation, viability and cell cycle analysis.

    No full text
    *<p>TAO vs. NS,</p>†<p>TAO vs. S; FC = fetal calf, NS = nonsmokers, S = smokers, TAO = Thromboangiitis obliterans.</p

    Levels of circulating progenitor cells and PBMCs in TAO patients.

    No full text
    <p>Levels of CD45<sup>dim</sup>CD34<sup>+</sup>, CD45<sup>dim</sup>CD34<sup>+</sup>CD133<sup>+</sup>, and CD45<sup>dim</sup>CD34<sup>+</sup>VEGFR2<sup>+</sup> progenitor cells were measured by flow cytometry. The numbers of progenitor cells (PC) were expressed as cells per 10<sup>5</sup> peripheral blood mononuclear cells (PBMCs). A) Levels of CD45<sup>dim</sup>CD34<sup>+</sup> PC, B) levels of CD45<sup>dim</sup>CD34<sup>+</sup>CD133<sup>+</sup> PC, C) levels CD45<sup>dim</sup>CD34<sup>+</sup>VEGFR2<sup>+</sup> PC, D) proportion of CD45<sup>dim</sup>CD34<sup>+</sup>VEGFR2<sup>+</sup> PC on CD45<sup>dim</sup>CD34<sup>+</sup> PC, E) number of PBMCs per ml of blood. Data are presented as medians, with 25/75 percentiles (boxes) and 10/90 percentiles (bars), (n = 12 in each group). *P<0.05, **P<0.01, ***P<0.001; NS = nonsmokers, S = smokers, TAO = Thromboangiitis obliterans.</p

    Low Dose Proteasome Inhibition Affects Alternative Splicing

    No full text
    Protein degradation by the ubiquitin proteasome system ensures controlled degradation of structural proteins, signaling mediators, and transcription factors. Inhibition of proteasome function by specific proteasome inhibitors results in dose-dependent cellular effects ranging from induction of apoptosis to protective stress responses. The present study seeks to identify nuclear regulators mediating the protective stress response to low dose proteasome inhibition. Primary human endothelial cells were treated with low doses of the proteasome inhibitor MG132 for 2 h, and proteomic analysis of nuclear extracts was performed. Using a 2-D differential in gel electrophoresis (DIGE) approach, we identified more than 24 splice factors to be differentially regulated by low dose proteasome inhibition. In particular, several isoforms of hnRNPA1 were shown to be increased, pointing toward altered posttranslational modification of hnRNPA1 upon proteasome inhibition. Elevated levels of splice factors were associated with a different alternative splicing pattern in response to proteasome inhibition as determined by Affymetrix exon array profiling. Of note, we observed alternative RNA processing for stress associated genes such as caspases and heat shock proteins. Our study provides first evidence that low dose proteasome inhibition affects posttranscriptional regulation of splice factors and early alternative splicing events

    Low Dose Proteasome Inhibition Affects Alternative Splicing

    No full text
    Protein degradation by the ubiquitin proteasome system ensures controlled degradation of structural proteins, signaling mediators, and transcription factors. Inhibition of proteasome function by specific proteasome inhibitors results in dose-dependent cellular effects ranging from induction of apoptosis to protective stress responses. The present study seeks to identify nuclear regulators mediating the protective stress response to low dose proteasome inhibition. Primary human endothelial cells were treated with low doses of the proteasome inhibitor MG132 for 2 h, and proteomic analysis of nuclear extracts was performed. Using a 2-D differential in gel electrophoresis (DIGE) approach, we identified more than 24 splice factors to be differentially regulated by low dose proteasome inhibition. In particular, several isoforms of hnRNPA1 were shown to be increased, pointing toward altered posttranslational modification of hnRNPA1 upon proteasome inhibition. Elevated levels of splice factors were associated with a different alternative splicing pattern in response to proteasome inhibition as determined by Affymetrix exon array profiling. Of note, we observed alternative RNA processing for stress associated genes such as caspases and heat shock proteins. Our study provides first evidence that low dose proteasome inhibition affects posttranscriptional regulation of splice factors and early alternative splicing events

    Blood lipid levels after intervention.

    No full text
    <p>Box plot of total cholesterol (<b>A</b>) and LDL cholesterol (<b>B</b>) levels in serum after supplementation with the indicated diets for 4 weeks. The boxes contain 50% of individual values; the middle line within the box represents the median. Total and LDL cholesterol levels were significantly lower in the lycopene group. *P<0.05 compared to cholesterol and placebo. n = 9 animals per group.</p

    Plasma total lycopene levels in individual rabbits after feeding the indicated diets for 4 weeks.

    No full text
    <p>Cholesterol: animals were fed with a high-cholesterol diet (0.5% cholesterol); Placebo: high-cholesterol diet supplemented with placebo beadlets containing all ingredients of lycopene beadlets except lycopene; Lycopene: high-cholesterol diet supplemented with 5 mg lycopene/kg body weight/day as lycopene beadlets. The number in the graph represents the mean ± SD. n = 9 animals per group.</p
    corecore